Cupid Guides For ₹725-750 Crore FY27 Revenue, Targets ₹1,500 Crore By FY29

Market snapshot: Cupid Limited has significantly upgraded its financial guidance, now projecting consolidated revenue of ₹725-750 crore and net profit of ₹210-225 crore for the ongoing fiscal year 2027. Additionally, the company has set an ambitious medium-term target to achieve ₹1,500 crore in revenue by fiscal year 2029, reflecting strong operational visibility across its international B2B healthcare segments and a rapidly expanding domestic consumer presence. This marks a substantial upward revision from the initial projections of ₹600 crore revenue and ₹180 crore profit set earlier this year.

Data Snapshot

• Consolidated revenue from operations grew 142% YoY to ₹156.98 crore in Q1 FY27, compared to ₹64.75 crore in Q1 FY26.
• Consolidated Net Profit surged 194% YoY to ₹44.15 crore in Q1 FY27, up from ₹15 crore in Q1 FY26.
• Operating EBITDA soared 265% YoY to ₹60 crore, leading to an EBITDA margin expansion of 1,127 basis points YoY to 39%.
• The company has set an upgraded medium-term revenue target of ₹1,500 crore to be achieved by fiscal year 2029.

What's Changed

• Initial targets of ₹600 crore revenue and ₹180 crore profit for FY27, set in May 2026, have been significantly upgraded to ₹725-750 crore and ₹210-225 crore respectively.
• The medium-term revenue target for FY29 has been raised to ₹1,500 crore from the previous projection of ₹1,150 crore outlined in the Q4 FY26 investor presentation.
• Operational profitability has expanded sharply with EBITDA margins reaching 39% in Q1 FY27, up from 27.73% in the same period of the previous year, supported by a 10% export portfolio price hike.

Key Takeaways

• Strategic transition from a specialized sexual wellness company to a diversified consumer personal care and wellness brand is driving multi-engine growth.
• Strong order visibility across global B2B procurement networks, including institutional tenders and long-term agreements like the PFSCM, supports the elevated outlook.
• Future volume scalability is secured with the upcoming operationalization of the Palava manufacturing facility, expected to expand existing capacity by 1.5 times.
• Promoter group alignment remains highly robust as evidenced by continuous open-market purchases by CMD Aditya Kumar Halwasiya.

SAHI Perspective

Cupid's continuous upward revisions of its near-term and medium-term guidance underscore a profound structural transformation under the current management. By successfully expanding into high-margin B2C wellness and personal care verticals alongside its core B2B condom manufacturing franchise, Cupid is unlocking significant operating leverage. The Q1 FY27 margin expansion to 39% demonstrates that the pricing power established in international markets (evidenced by a 10% export price hike) is translating into highly sustainable, high-quality earnings. While the target of ₹1,500 crore by FY29 is highly ambitious—requiring a strong compound annual growth rate—the combination of capacity expansion, strategic retail partnership deployment, and robust global tender pipelines suggests the company's strategic runway is exceptionally solid.

Market Implications

The upward guidance revisions are likely to sustain strong investor sentiment, which has already pushed the stock to new heights with multibagger gains over the past year. Cupid's reclassification into Group 'A' on the BSE will continue to attract institutional interest and enhance trading liquidity. Furthermore, the robust balance sheet with zero pledged promoter shares as of late 2025 reduces corporate governance risk, making it a highly attractive small-cap compounding story for long-term investors.

Trading Signals

Market Bias: Bullish

Cupid's upgraded FY27 revenue guidance of ₹725-750 crore and PAT of ₹210-225 crore, backed by a blockbuster Q1 FY27 net profit surge of 194% YoY to ₹44.15 crore, demonstrates robust business momentum and strong operating leverage.

Overweight: Consumer Wellness, Personal Goods, FMCG Healthcare

Trigger Factors:

• Execution of global B2B healthcare tenders and international orders.
• Palava manufacturing facility commissioning and commercial production scale-up.
• Quarterly EBITDA margin sustainability at or near the 39% level.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global and domestic personal care and sexual wellness market is experiencing a shift toward premium, high-margin consumer products. Cupid's strategy of pairing traditional B2B contract manufacturing with a robust domestic B2C FMCG footprint (such as personal lubricants, fragrances, and skin care) allows it to bypass traditional distribution bottlenecks. Furthermore, the domestic in-vitro diagnostics (IVD) kit sector offers a strong near-term pipeline as state governments scale public healthcare tenders, where Cupid has actively expanded its manufacturing footprint.

Key Risks to Watch

• Any adverse volatility in latex and other raw material costs could put pressure on the expanded 39% EBITDA margins.
• Delay in regulatory approvals or CE certifications for new products, particularly in the diagnostics and medical devices portfolio, could slow down international execution.
• Since a significant portion of revenues is derived from exports, adverse fluctuations in the USD/INR exchange rate, despite hedging practices, present a potential headwind.

Recent Developments

On August 25, 2026, promoter and CMD Aditya Kumar Halwasiya acquired 97,392 equity shares in the open market, raising his individual stake to 33.54%, and total promoter holding to 46.49%. Earlier on July 29, 2026, Cupid deployed USD 5 million (approx. ₹41.7 crore) as a follow-on investment in GII Healthcare Investment Limited. On July 11, 2026, Cupid was officially reclassified to the BSE's Group 'A' category.

High Performance Trading with SAHI.